_active.jpg)
The US Food and Drug Administration (FDA) has approved Japan-based Takeda Pharmaceutical Company and its US subsidiary’s new biologic therapy, Entyvio (vedolizumab), for treating adults with moderately to severely active ulcerative colitis (UC) and Crohn’s disease (CD).
Currently, Entyvio is approved for inducing and maintaining clinical response and remission, improving endoscopic appearance of the mucosa.
Go deeper with GlobalData
The drug will also achieve corticosteroid-free remission in adult patients with moderately to severely active UC who have had an inadequate response with, lost response to, or were intolerant to a tumour necrosis factor (TNF) blocker or immunomodulator; or had an inadequate response with, were intolerant to, or demonstrated dependence on corticosteroids.
Northwestern University Feinberg School of Medicine medical director Stephen Hanauer said Entyvio is a new option that works to block important contributors to the chronic inflammation that is a hallmark of ulcerative colitis and Crohn’s disease.
"The clinical trial programme evaluated the efficacy and safety profile of Entyvio and demonstrated that Entyvio has the potential to help adult patients with moderately to severely active UC or CD successfully manage their disease," Hanauer said.
The FDA approved dose of Entyvio is 300mg, which will be infused intravenously over 30 minutes at zero, two and six weeks, then every eight weeks thereafter.
How well do you really know your competitors?
Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.
Thank you!
Your download email will arrive shortly
Not ready to buy yet? Download a free sample
We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form
By GlobalDataAccording to the company, patients should be observed during infusion and until the completion of the infusion.
Takeda Pharmaceuticals USA president Douglas Cole said patients with moderately to severely active ulcerative colitis or Crohn’s disease, and the healthcare professionals who care for them, need additional new treatment options.
"Entyvio reflects an expansion of Takeda’s commitment to supporting patients with gastrointestinal disorders," Cole said.
In March 2014, Takeda secured a positive opinion for Entyvio to treat adults with moderately to severely active UC and CD from the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP).
At present, the company is awaiting response from the European Commission on approval for marketing authorisation of Entyvio.
Filing of the Biologics License Application (BLA) was based on the largest Phase III clinical trial programme carried out to date simultaneously evaluating both UC and CD patient populations in four clinical studies involving 2,700 patients in nearly 40 countries.
Three studies in the programme were randomised, double-blind, placebo-controlled trials including GEMINI I (UC Trials I and II), GEMINI II (CD Trials I and III) and GEMINI III (CD Trial II).
These three trials evaluated adult patients with moderately to severely active UC or CD who had an inadequate response or intolerance to immunomodulator therapy, inadequate response, loss of response, or intolerance to a TNF blocker; or were corticosteroid dependent or had an inadequate response or intolerance to corticosteroids.
Image: H&E stain of a colonic biopsy showing a crypt abscess, a classic finding in ulcerative colitis. Photo: courtesy of KGH.
